• BrainAurora disclosed publication of a large retrospective real-world study in BMC Medicine on dosing for its pediatric cognitive digital therapeutic.
• Results have already been presented via the journal publication, not a future conference readout.
• Training was linked to improved cognitive performance, with benefits leveling off beyond an optimal daily use range.
• Findings also supported age- and sex-specific dosing, pointing to more individualized treatment plans for children with cognitive impairment.
• Management framed the publication as strengthening its evidence base for digital therapeutics, supporting product positioning in pediatric cognitive care.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Brainaurora Medical Technology Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260909-12325943), on September 09, 2026, and is solely responsible for the information contained therein.